We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Becton Dickinson and Company | NYSE:BDX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 1.42 | 0.61% | 235.00 | 236.445 | 233.68 | 234.14 | 1,921,790 | 01:00:00 |
From May 2023 to May 2024
By Will Feuer
Becton Dickinson's sales and adjusted earnings outlook for fiscal 2024 are below Wall Street analysts' expectations, dragged down by currency fluctuations and softening demand for Covid-19 testing.
The medical-device maker is targeting fiscal-year revenue of $20.1 billion to $20.3 billion, below the $20.35 billion that analysts surveyed by FactSet expected.
The company said it is targeting organic sales growth of 5.25% to 6.25%, including a more than 25-basis-points hit from the expected decline in Covid-19-only testing demand. Foreign-exchange rates are expected to reduce sales growth by about 75 basis points.
Becton Dickinson is targeting adjusted earnings for the year of $12.70 a share to $13.00 a share, below the $13.48 a share that analysts expected, according to FactSet.
Write to Will Feuer at Will.Feuer@wsj.com
(END) Dow Jones Newswires
November 09, 2023 07:08 ET (12:08 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Becton Dickinson Chart |
1 Month Becton Dickinson Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
